Skip to Content

Notice

Prospective Grant of Exclusive Patent License: Treatment of Type I Diabetes and its Comorbidities

A Notice by the National Institutes of Health on 08/07/2018

  • PDF
  • Document Details
  • Document Dates
  • Table of Contents
  • Public Comments
  • Regulations.gov Data
  • Sharing
  • Print
  • Document Statistics
  • Other Formats
  • Public Inspection
Published Document: 2018-16836 (83 FR 38707)

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Document Headings

Document headings vary by document type but may contain the following:

  1. the agency or agencies that issued and signed a document
  2. the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to
  3. the agency docket number / agency internal file number
  4. the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions

See the Document Drafting Handbook for more details.

Department of Health and Human Services
National Institutes of Health

AGENCY:

National Institutes of Health, HHS.

ACTION:

Notice.

SUMMARY:

The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent License to Inversago Pharma, Inc., located in Montreal, Quebec, Canada, to practice the inventions embodied in the patent applications ( printed page 38708) listed in the Supplementary Information section of this notice.

DATES:

Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development August 22, 2018 will be considered.

ADDRESSES:

Requests for copies of the patent applications, inquiries, and comments relating to the contemplated exclusive patent license should be directed to: Michael Shmilovich, Esq., Senior Licensing and Patent Manager, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479, phone number 301-435-5019, or .

SUPPLEMENTARY INFORMATION:

The following and all continuing U.S. and foreign patents/patent applications thereof are the intellectual properties to be licensed under the prospective agreement to Inversago Pharma, Inc.:

HHS Reference No. Patent No. or application No. Filing date Title
E-282-2012-0-US-01 61/725,949 November 13, 2012 Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-PCT-02 PCT/US2013/069686 November 12, 2013 Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-03 9,765,031 November 12, 2013 Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-CA-04 2889697 April 27, 2015 Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-EP-05 13802153.0 June 01, 2015 Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-IN-06 3733/DELNP/2015 May 1, 2015 Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-JP-07 2015-542015 May 11, 2015 Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-CN-08 201380069389.9 July 3, 2015 Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-09 15/674,365 August 10, 2017 Cannabinoid Receptor Mediating Compounds.
E-282-2012-0-US-10 15/674,333 August 10, 2017 Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-US-01 61/991,333 May 9, 2014 Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-US-01 62/171,179 June 4, 2015 Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-PCT-02 PCT/US2016/035291 June 1, 2016 Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-EP-05 16728547.7 June 1, 2016 Cannabinoid Receptor Mediating Compounds.
E-282-2012-1-US-08 15/579,123 December 1, 2017 Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-PCT-02 PCT/US2015/029946 May 8, 2015 Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-AU-03 2015255765 November 7, 2016 Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-CA-04 2948349 May 8, 2015 Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-EP-06 15728668.3 May 8, 2015 Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-CN-05 201580028788.X May 8, 2015 Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-IN-07 201637038171 November 8, 2016 Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-JP-08 2017-511558 May 8, 2015 Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-US-09 15/309,728 November 8, 2016 Cannabinoid Receptor Mediating Compounds.
E-140-2014-0-HK-10 17105705.6 June 9, 2017 Cannabinoid Receptor Mediating Compounds

The patent rights in these inventions have been assigned to the Government of the United States of America. The prospective exclusive patent license territory will be granted worldwide and in a field of use not broader than human therapeutics for type I diabetes and its comorbidities diabetic nephropathy, chronic kidney disease, diabetic retinopathy, and peripheral and autonomic neuropathy.

The invention covered by the patents and patent applications pertaining to HHS Ref. No. E-282-2012-0 pertain to cannabinoid receptor 1 (CN1 R) inverse agonists. CN1 R activation plays a key role in appetitive behavior and metabolism. Of importance as a therapeutic target here is that the receptor is expressed in both peripheral tissue as well as the central nervous system. The invention is a class of pyrazole compounds that act as CN1 receptor inverse agonists and have been shown effective at reducing obesity and its associated metabolic consequences while having no experimentally discernable neuropsychotropic side effects that are considered adverse such as the earlier antagonists rimonabant. These CN1 R receptor compounds were developed with the goals of limiting their brain penetrance without losing their metabolic efficacy due to CN1 inverse agonism, and having a primary metabolite directly targeting enzymes involved in inflammatory and fibrotic processes associated with metabolic disorders. The patent rights cover both compositions of matter and methods of use.

The inventions covered by HHS Ref. E-140-2014-0 also pertain to pyrazole CN1 R receptor inverse agonists. In addition, some of these compounds also have a direct inhibitory effect on inducible nitric oxide synthase (iNOS), whereas another group of the compounds directly activates AMP kinase. There is evidence that the metabolic effects of endocannabinoids are mediated by CN1 receptors in peripheral tissues. These dual-target compounds may be useful for treating metabolic disease and related conditions such as obesity and diabetes and their complications, including liver or kidney fibrosis, without the dangerous the side effects.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive patent license will be royalty bearing and may be granted unless within fifteen (15) days from the date of this published notice, the NHLBI receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

Complete applications for a license in the prospective field of use that are timely filed in response to this notice will be treated as objections to the grant of the contemplated exclusive patent license.

Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act,5 U.S.C. 552.

Dated: July 25, 2018.

Michael A. Shmilovich,

Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.

[FR Doc. 2018-16836 Filed 8-6-18; 8:45 am]

BILLING CODE 4140-01-P

Published Document: 2018-16836 (83 FR 38707)